Targeting the insulin-like growth factor pathway in hepatocellular carcinoma

查看全文 作　　者：Mónica Enguita-[1]Germán;Puri [1]Fortes

机构地区：[1]Department of Hepatology and Gene Therapy,Center for Applied Medical Research

出　　处：《World Journal of Hepatology》索引2014年第6卷第10期,共22页

基　　金：Supported by Ministerio de Ciencia e Innovacion BIO2009/09295 and SAF2012-40003;FEDER funding,funds from the'UTE project CIMA';the project RNAREG(CSD2009-00080);from The Ministry of Science and Innovation under the programme CONSOLIDER INGENIO 2010 摘　　要：Hepatocellular carcinoma(HCC) is the third leading cause of cancer-related deaths worldwide. Only 30%-40% of the patients with HCC are eligible for curative treatments, which include surgical resection as the first option, liver transplantation and percutaneous ablation. Unfortunately, there is a high frequency of tumor recurrence after surgical resection and most HCC seem resistant to conventional chemotherapy and radiotherapy. Sorafenib, a multi-tyrosine kinase inhibitor, is the only chemotherapeutic option for patients with advanced hepatocellular carcinoma. Patients treated with Sorafenib have a significant increase in overall survival of about three months. Therefore, there is an urgent need to develop alternative treatments. Due to its role in cell growth and development, the insulin-like growth factor system is commonly deregulated in many cancers. Indeed, the insulin-like growth factor(IGF) axis has recently emerged as a potential target for hepatocellular carcinoma treatment. To this aim, several inhibitors of the pathway have been developed suchas monoclonal antibodies, small molecules, antisense oligonucleotides or small interfering RNAs. However recent studies suggest that, unlike most tumors, HCC development requires increased signaling through insulin growth factor Ⅱ rather than insulin growth factor Ⅰ. This may have great implications in the future treatment of HCC. This review summarizes the role of the IGF axis in liver carcinogenesis and the current status of the strategies designed to target the IGF-Ⅰ signaling pathway for hepatocellular carcinoma treatment. 关键词：Hepatocellular carcinoma INSULIN Insulinlike GROWTH FACTOR Insulinlike GROWTH FACTOR receptor THERAPY TYROSINE KINASE inhibitor Antibody THERAPY

相关文献

参考文献（58）
引证文献（12）
耦合文献（95）

参考文献(58)

引证文献(12)

耦合文献(95)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Targeting the insulin-like growth factor pathway in hepatocellular carcinoma

参考文献(58)

引证文献(12)

耦合文献(95)

用户提示